Benign Prostatic Hyperplasia

Beschreibung

Pathophysiology, medications, CMs, Diagnostics
Mark George
Karteikarten von Mark George, aktualisiert more than 1 year ago
Mark George
Erstellt von Mark George vor etwa 11 Jahre
57
0

Zusammenfassung der Ressource

Frage Antworten
BPH Patho Static Component Proliferation of Glandular Epithelium (alterations of testosterone, estrogen, DHT)
BPH Patho Dynamic component Increase in prostatic smooth muscle tone linked to altered activity of PICs (possibly contributes to increased prostate contractility)
BPH Pharmacology Finasteride 5Alpha Reductase inhibitor Blocks conversion of testosterone into DHT Altered libido / Impotence
BPH Pharmacology Tamsulosin Alpha1a adrenoceptor antagonist blocks prostatic smooth muscle receptors :- decreases Ca++ availability (decreased prostate contractility) Postural hypotension / GIT
BPH diagnostics DRE (digital rectal exam) Physical exam determines the state and size of the external surface of the prostate gland
BPH Diagnostics PSA Blood test that measures the level of specific antigen produced by both benign and malignant prostate tissue
BPH Clinical Manifestations (Obstructive) proLONGed voiding. WEAK urinary stream. INCOMPLETE emptying. abdominal STRAINing. posturination DRIBBLE.
BPH Clinical manifestations (Irritative) nocturia bladder PAIN URGENT urination incontinence
BPH Clinical manifestations (Ureter obstruction) Bladder/kidney INFECTION acute urinary RETENTION RENAL INSUFFICIENcy HAEMATURIA
Zusammenfassung anzeigen Zusammenfassung ausblenden

ähnlicher Inhalt

Französische Revolution
Markus Grass
IKA-Theoriefragen Serie 04 (15 Fragen)
IKA ON ICT GmbH
Berliner Mauer - Quiz
Laura Overhoff
Blended Learning in der Schule umsetzen
Laura Overhoff
Evolutionsfaktoren
Xenia W.
Wortschatz Französisch 1. Angaben zur Person
l_u_n_a_19
U3 Netzwerkprotokolle
Lena A.
Vetie: Virofragen 2015
Johanna Tr
PR 2018/19 GESKO VO 1-6
Adrienne Tschaudi
Vetie Viro 2013
Laura Sieckmann
Vetie AVO 2020
M W